RAFAEL VALVERDE Rafael lives with obesity Mexico Novo Nordisk – a focused healthcare company Investor presentation Full year 2025 2 Novo Nordisk® Investor presentation Full year 2025 Forward-looking statements Novo Nordisk's statutory Annual Report 2025, Form 20-F, any quarterly financial reports, and written information released, shown, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain certain forward-looking statements relating to the operating, financial an ...

Novo hired a new US chief charged with turning around the company’s most important market where mounting pricing pressure and intensifying competition are eroding its grip on the obesity-drug boom https://t.co/PTyHGpL1Te ...

Core Viewpoint - Novo Nordisk A/S anticipates a sales decline this year due to increased competition for its drugs Ozempic and Wegovy, alongside the impact of US government initiatives to reduce drug prices [1][3]. Sales Outlook - Sales at constant exchange rates are projected to decrease by 5% to 13%, contrasting with analysts' expectations of a 1.4% decline [1]. - The last annual sales drop for the company occurred in 2017, primarily due to a price war over insulin in the US [2]. Competitive Landscape - Novo Nordisk faces intensified competition, particularly from Eli Lilly & Co.'s Zepbound, which has gained market leadership in the US [2]. - The emergence of generic versions of Ozempic is expected in international markets later this year, further challenging sales [2]. Market Dynamics - Despite an anticipated expansion in the global GLP-1 market, factors such as lower realized pricing and the loss of exclusivity for semaglutide in several countries are expected to negatively impact revenues [3]. Investor Sentiment - The company is working to regain investor confidence following a significant decline in share value in 2025 [4]. - A new stock buyback program worth up to 15 billion Danish kroner (approximately $2.4 billion) has been announced to bolster investor sentiment [4].

Core Viewpoint - Novo Nordisk's CEO Mike Doustdar provided a pessimistic outlook on the company's prospects for 2026 during a media briefing following the pre-announcement of earnings [1] Group 1 - The company pre-announced its earnings a day prior to the media engagement [1] - CEO Mike Doustdar expressed concerns regarding the company's future performance [1]

Pharmaceuticals - Novo Nordisk is set to receive FDA approval for the high-dose version of its weight-loss drug, Wegovy, expected in Q1 2026, indicating strong international demand following positive early signs from the UK launch [1] Currency Markets - The Japanese Yen has declined 0.6% against the US Dollar, trading at 156.67, with the USD/JPY exchange rate rising to 156.4610, a 0.44% increase from the previous session, driven by currency market volatility and differing monetary policies [2] US Policy - US Senators are advocating for a $70 billion funding initiative to support critical minerals, aiming to reduce dependence on foreign sources for essential materials like gallium, cobalt, lithium, and rare earth elements, which are vital for technology, defense, and electric vehicles [3] Global Energy - The Kremlin acknowledges India's efforts to diversify its oil supplies, highlighting the changing dynamics in global energy markets as India seeks to broaden its energy import sources beyond discounted Russian oil [4] Eurozone Economy - Italy's January Consumer Price Index (CPI) EU Harmonized year-over-year preliminary reading is at 1.0%, above the estimated 0.8% but down from 1.2% the previous month, indicating signs of moderation in inflation [5]

整理 | GLP1减重宝典内容团队 在 GLP-1 神话持续两年之后，资本市场第一次用极端方式表达了不耐烦。2026 年 2 月初，诺和诺德 发布最新年度财报及业绩指引后，公司股 价在一个交易日内暴跌约 14%，创下近几年最大单日跌幅。这一反应并非源自司美格鲁肽卖得不好，恰恰相反，这款"药王"仍在创造历史级别 的销售规模，而是市场开始意识到，诺和诺德的增长故事，已经进入一个高风险、高不确定性的阶段。 从财报表面看，诺和诺德依然站在行业巅峰。2025 年，公司核心产品司美格鲁肽全系列实现销售额超过 2280 亿丹麦克朗，约合 2500 亿元人 民币，占公司总营收的比例进一步抬升。无论是降糖版 Ozempic，还是减重版 Wegovy，依旧供不应求，多个市场仍存在产能受限问题。如果 只看历史数据，这是一份足以支撑高估值的成绩单。 但市场真正关注的，并不是过去一年卖了多少，而是未来还能以什么样的速度继续增长。引爆股价下跌的关键，是诺和诺德给出的 2026 年业 绩指引。公司预计，2026 年全年营收按固定汇率计算将同比下滑 5% 至 13%，这一预期不仅远低于市场此前的增长假设，甚至意味着在 GLP- 1 需求仍然 ...

点击关注，追踪最新GLP-1资讯 整理 | GLP1减重宝典内容团队 在全球制药史上，很少有单一分子能够在如此短时间内撬动如此规模的市场。2 月 4 日，诺和诺德 披露 2025 年财报，其核心产品司美格鲁肽 全系列药物全年销售额达到 2282.88 亿丹麦克朗，约合 2508 亿元人民币，同比增长超过 10%，继续刷新全球单一药物销售纪录。 从具体产品结构看，司美格鲁肽已形成罕见的"三线并行"商业格局。降糖版注射剂 Ozempic（中国商品名诺和泰）全年销售 1270.89 亿丹麦克 朗，仍是全球处方量最大的 GLP-1 药物；减重版注射剂 Wegovy（中国商品名诺和盈）实现销售 791.06 亿丹麦克朗，成为全球增长最快的处 方减肥药；口服司美格鲁肽片剂（中国商品名诺和忻）销售 220.93 亿丹麦克朗，虽体量相对较小，但已成为 GLP-1 口服化路径的关键支点。 在中国市场，司美格鲁肽三大产品线合计实现销售 68.15 亿丹麦克朗，约合 74.9 亿元人民币。这一规模在诺和诺德全球版图中占比不高，却 被视为最具战略意义的增量市场之一。 从全球视角看，司美格鲁肽当前已稳居全球药物销售榜首，但其"年度药王 ...

Group 1 - The core viewpoint of the news is that Novo Nordisk's stock has experienced significant declines following disappointing sales forecasts, with a projected annual sales decline for the first time in nine years [1] - In Q4, Novo Nordisk's sales decreased by 7.6% year-on-year, although this was better than analyst expectations, and sales of the weight loss drug Wegovy also exceeded forecasts [1] - The company anticipates a sales and operating profit decline of 5%-13% by 2026, while analysts predict declines of 1.4% and 3.1% respectively [1] Group 2 - The CEO of Novo Nordisk indicated that the company will face "unprecedented pricing pressure" by 2026 [1] - The global GLP-1 market is expected to continue expanding, which may allow the company to increase sales volume, although at lower actual prices [1] - Following the forecast of declining sales and profits, traders expect Novo Nordisk's stock to drop by 13%-15% [1]

Core Viewpoint - Jefferies analysts indicate that Novo Nordisk's 2026 outlook suggests a significant downward adjustment is needed for market average expectations [1] Group 1: Sales and Profit Outlook - The revised full-year outlook and management changes are expected to disappoint investors [1] - Sales expectations imply that market average forecasts need to be adjusted down by a high single-digit percentage, potentially not accounting for aggressive assumptions regarding oral Wegovy [1] - Operating profit outlook suggests that market average expectations need to be lowered by a low double-digit percentage [1] Group 2: Management Changes - Dave Moore, head of U.S. operations, will leave for personal reasons, with Jamey Millar from UnitedHealth set to replace him [1] - Ludovic Helfgott, head of product and portfolio strategy, will also depart to seek new opportunities, with Hong Chow from Merck KGaA's healthcare division taking over [1] Group 3: Stock Performance - Following the news, the company's stock price dropped by 18% [1]

Group 1 - The stock experienced a significant decline of 19% at the opening bell in Copenhagen [1] - The company's outlook for the upcoming year did not meet investor expectations, leading to the stock drop [1]